May 30, 2018
China Drug Administration approves Gilead’s chronic hepatitis C virus infection drug
Gilead Sciences has gotten the approval from the China Drug Administration (CDA) of Epclusa for the treatment of adults with…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: hepatitis C virus
August 2, 2017
FDA OK’s Gilead Sciences’s hepatitis C drug
The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gilead Sciences’s Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.
February 7, 2017
Gilead’s income driven down by lower sales of hepatitis C virus products
Gilead Sciences has reported net income for the fourth quarter 2016 of $3.1 billion, which is $1.6 billion less compared to same period last year.
November 24, 2015
Penn Researchers, Diplomat study shows: Nearly 50% Medicaid hepatitis C patients denied therapies as not considered “a medical necessity”
Nearly 50 percent of Medicaid patients infected with chronic hepatitis C virus (HCV) whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they were not considered “a medical necessity.”
October 6, 2015
Merck: Results of Phase 3 Study of Investigational Chronic Hepatitis C Therapy
Merck has announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection.